Summary
A series of bagged recursive partitioning models for log(BB) is presented. Using a LGO-CV, three sets of physical property descriptors are evaluated and found to have Q2 values of 0.51 (CPSA), 0.53 (Ro5x) and 0.53 (MOE). Extrapolating these models to Pfizer chemical space is difficult due to P-glycoprotein (P-gp) mediated efflux. Low correlation coefficients for this test set are improved (R 2=0.39) when compounds known to be P-gp substrates or statistical extrapolations are removed. The use of simple linear models for specific chemical series is also found to improve the correlation over a limited chemical space.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Young R.C., et al., (1988) J. Med. Chem. 31: 656
Abraham M.H., Chadha H., Mitchell R.C., (1994) J. Pharm. Sci. 83: 1257
Lombardo F., Blake J.F., Curatolo W.J., (1996) J. Med. Chem. 39: 4750
Platts J.A., et al., (2001) Eur. J. Med. Chem. 36: 719
Clark D.E., (1999) J. Pharm. Sci. 88: 815
Kelder J., et al., (1999) Pharma. Res. 16: 1514
Iyer M., et al., (2002) Pharma. Res. 19: 1611
Doniger S., Hofmann T., Yeh J., (2002) J. Comp. Bio. 9: 849
van de Waterbeemd H., Kansy M., (1992) Chimia. 46: 299
Chadha H., Abraham M.H., Mitchell R.C., (1994) Bio. Med. Chem. Lett. 4: 2511
Sippl W., (2002) Curr. Med. Chem.: Central Nervous Syst. Agents. 2: 211
Atkinson F., et al., (2002) Curr. Med. Chem.: Central Nervous Syst. Agents. 2: 229
Penzotti J.E., Landrum G.A., Putta S., (2004) Curr. Opinion Drug Discovery Dev. 7: 49
Lipinski, C.A., In Spellmeyer D.C., (Ed.), Annual Reports in Computational Chemistry, Elsevier: Amsterdam, pp. 155–168
Norinder U., Sjoberg P., Osterberg T., (1998) J. Pharm. Sci. 87:952
Osterber T., Norinder U., (2001) Eur. J. Pharm. Sci. 12: 327
Luco J.M., (1999) J. Chem. Inf. Comput. Sci. 39: 396
Rose K., Hall L.H., Kier L.B., (2002) J. Chem. Inf. Comput. Sci. 42: 651
Ajay G.W., Bemis, Murcko M.A., (1999) J. Med. Chem. 42: 4942
Crivori P., et al., (2000) J. Med. Chem. 43: 2204
Adenot M., Lahana R., (2004) J. Chem. Inf. Comput. Sci. 44: 239
Maclin R., Opitz D., (1999) J. Art. Intelligence Res. 11: 169
Stanton D.T., Jurs P., (1990) C., Anal. Chem. 62: 2323
Lipinski C.A., et al., (1997) Adv. Drug Del. Rev. 23: 3
Labute P., (2000) J. Mol. Graphics Model. 18: 464
Cruciani G., et al., (2000) J. Mol. Struct.: THEOCHEM.503: 17
Cruciani, G., Pastor, M. and Clementi, S., In: Gundertofte, K. and Jorgensen, F.E., (Eds.), Molecular Modeling and Prediction of Bioactivity, Kluwer Academic/Plenum Publishers: New York, 2000, 73pp
Maw H.H., Hall L.H., (2000) J. Chem. Inf. Comput. Sci. 40: 1270
Kimberly R., Hall L.H., (2002) J. Chem. Inf. Comput. Sci. 42: 651
Gasteiger J., Rudolph C., (1990) J. Sadowski, Tetrahedron Comp. Method. 3: 537
Hawkins G.D., et al., 2003 AMSOL. University of Minnesota: Minneapolis
Hawkins G.D., Cramer C.J., Truhlar D.G., (1996) J. Phys. Chem. 100: 19824
Chambers C.C., et al., (1996) J. Phys. Chem. 100: 16385
Pearlman, R.S., In Valvani S.C. (Ed.), Physical Chemical Properties of Drugs, Marcel Dekker: New York, 1980
Andrews P.R., Craik D.J., Martin J.L., (1984) J. Med. Chem. 27: 1648
BioByte, CLOGP. 2005, BioByte Corp: Claremont, CA
Ertle P., Rohde B., Selter P., (2000) J. Med. Chem. 43: 3714
Moriguchi I., et al., (1992) Chem. Pharmacol. Bull. 40: 127
Chemical Computing Group Inc, C., 2000 Molecular Operating Environment. Chemical Computing Group Inc: Montreal
Gasteiger J., Marsili M., (1980) Tetrahedron, 36: 3219
Kalvass J.C., Maurer T.S., (2002) Biopharma. Drug Disposition, 23: 327
Waterbeemd, H.v.d., Smith D.A., Jones B.C., (2001) J. Comp.-Aided Mol. Design. 15: 273
Brejc K., et al., (2001) Nature 411: 269
Iven H., Feldbusch E., (1983) Naunyn-Schmiedeberg’s Arch Pharmacol. 324: 153
Timmermans P.B.M.W.M., Brands A., Van Zwieten A., (1977) Arch. Pharmacol. 300: 217
Cvetkovic M., et al., (1999) Drug Metabol. Dispos. 27: 866
de Lange E.C.M., et al., (1994) Brain Research, 666: 1
Miyagi N., et al., (1986) J. Pharmacobio-Dynamics 9: 704
Rizk M., Curro F.A., Abdel-Rahman M.S., (1995) Pharmacol. Commun. 6: 295
Bickel M., Gerny R., (1980) J. Pharmacy Pharmacol. 32: 669
Dambisya Y.M., Chan K., Wong C.-L., (1992) J. Pharmacy Pharmacol. 44: 687–690
Cox D.S., et al., (2001) J. Pharm. Sci. 90: 1540
Chou R.C., Levy G., (1981) J. Pharm. Exp. Therapeutics 219: 42
Kunsman G.W., Rohrig T.P., (1993) Am. J. Forensic Med. Pathol. 14: 48
Yata N., et al., (1990) Pharma. Res. 7: 1019
Vajda F.J.E., et al., (1981) Neurology 31: 486
Bolo N.R., et al., (2000) Neuropsychopharmacology 23: 428
Lefebvre M., et al., (1999) Life Sci. 64: 805
Hosseini-Yeganeh M., Mclachlan A.J., (2001) J. Pharm. Sci. 90: 1817
Cheng F.C., et al., (2002) J. Chromatography, A. 949: 35
Borg N., Stahle L., (1998) Antimicrob. Agents Chemother. 42: 2174
Ibrahim S.S., et al., (1996) Antivirial Chem. Chemother. 7: 167
Choo E.F., et al., (2000) Drug Metabolism Disposition 28: 655
Anderson B.D., et al., (1990) J. Pharm. Exp. Therapeutics 253: 113
Glynn S.L., Yazdanian M., (1998) J. Pharm. Sci. 87: 306
Bolander H.G., Wahlstrom G., (1984) Neuropharmacology 23: 977
Bolander H.G., Wahlstrom G., Norberg L., (1984) Acta. Phar. et. Tox. 54: 33
Lin Y.-J., et al., (1973) Chem. Pharmacol. Bull. 21: 2749
Arendt R.M., et al., (1987) Psychopharmacology 93: 72
Mandema J., Kuck W.M.T., Danhof M., (1992) Br. J. Pharmacol. 105: 164
Scavone J.M., et al., (1987) Arzneim.-Forsch. 37: 2
Lin J.H., Chen I.-W., Lin T.-H., (1994) J. Pharm. Exp. Therapeutics 271: 1197
Baselt R.C., 2002 Disposition of Toxic Drugs and Chemicals in Man, 6 Foster City, CA: Chemical Toxicology Institute
Cruickshank J.M., et al., (1980) Clin. Sci. 59: 453s
Arendt R.M., et al., (1984) Cardiology 71: 307
Matsui K., et al., (1999) Drug Metabol. Disposition 27: 1406
Kewitz H., (1997) Drugs Today 33: 265
Kosasa T., et al., (2000) Eur. J. Pharmacol. 389: 173
Vezzani A., et al., (1989) J. Pharm. Exp. Therapeutics, 249: 278
Kuroda S., et al., (2001) Chem. Pharmacol. Bull. 49: 988
Calder J.A.D., Ganellin C.R., (1994) Drug Design Discovery 11: 259
Polli J.W., et al., (2003) J. Pharm. Sci. 92: 2082
Pong S.F., Huang C.L., (1974) J. Pharm. Sci. 63: 1527
Brown E.A., et al., (1986) Br. J. Pharmacol. 87:569
Barkai A.I., Suckow R.F., Cooper T.B., (1984) J. Pharm. Exp. Therapeutics. 230: 330
Doran A., et al., (2005) Drug Metabol. Disposition 33:165
Hirose H., et al., (2001) J. Pharm. Exp. Therapeutics 297:790
Schmalzing G., (1977) Drug Metabol. Disposition 5: 104
Tsuneizumi T., Babb S.M., Cohen B.M., (1992) Biol. Psychiatr. 32: 817
Sunderland T., Cohen B.M., (1987) Psychiatr. Res. 20: 299
Hu O.Y.-P., Curry S.H., (1989) Biopharma. Drug Disposition 10: 537
Yeleswaram K., et al., (1995) Res. Comm. Mol. Pathology Pharmacol. 89: 27
Scales B., Cosgrove M.B., (1970) J. Pharm. Exp. Therapeutics 175: 338
Riah O., et al., (1998) Cell. Mol. Neurobiol. 18: 311
Ghosheh O.A., et al., (2001) Drug Metabol. Disposition 29: 645
Romano C., Goldstein A., Jewell N.P., (1981) Psychopharmacology 74: 310
Rowell P.P., Li M.,. (1997) J. Neurochem. 68: 1982
Schroeder D.H., (1983) J. Clin. Psychiatr. 44: 79
Kaplan G.B., et al., (1989) J. Pharm. Exp. Therapeutics 248: 1078
Wilkinson J.M., Pollard I., (1993) Dev. Brain Res. 75: 193
Terasaki T., et al., (1992) Int. J. Pharmaceutics 81: 143
Stahle L., (1991) Life Sci. 49: 1835
Ramzan I.M., Levy G., (1986) J. Pharm. Exp. Therapeutics 236: 708
Ohshima N., et al., (1995) Biol. Pharma. Bull. 18: 70
Argent D., D’Mello A.P., (1994) J. Pharm. Exp. Therapeutics 270: 512
Okuyama S., Aihara H., (1984) Jpn. J. Pharmacol. 35: 95
Van Belle K., et al., (1995) J. Pharm. Exp. Therapeutics 272: 1217
Overo K.F., Jorgensen A., Hansen V., (1970) Acta. Phar. et. Tox. 28: 81
Yang H., Wang Q., Elmquist W.F., (1996) Pharma. Res. 13: 1570
Von Moltke L.L., et al., (2004) Drug Metab. Disposition 32: 800
Aravagiri M., Yuwiler A., Marder S.R., (1998) Psychopharmacology 139: 356
Yang Z., et al., (1997) Pharma. Res. 14: 865
McNally W., et al., (1989) Pharma. Res. 6: 924
Pan W.-J., Hedaya M.A., (1999) J. Pharm. Sci. 88: 468
Brogden, R.N., et al., Drugs, 24 (1982) 360
Lobell M., Molnar L., Keseru G.M., (2002) J. Pharm. Sci. 92: 360
Hou T., Xu X., (2002) J. Mol. Model, 8: 337
Keseru G.M., Molnar L., (2001) J. Chem. Inf. Comput. Sci. 41: 120
Bennet B., et al., (2000) J. Biol. Chem. 275: 20647
Shearman M.S., et al., (2000) Biochemistry 39: 8698
Jakovljevic V., Banic B., Radunovic A., (1991) Eur. J. Drug. Met. Pharmacokinetics 16:171
Reavill C., et al., (1990) Neuropharmacology 29: 619
Pentel P.R., et al., (2000) Pharmacol. Biochem. Behavior 65: 191
Acknowledgements
We thank the Pfizer Groton CNS Pharmacokinetics Dynamics and Metabolism (PDM) group for helpful discussion and invaluable in vivo data measurements. We also thank David Potter (Pfizer, Groton Non-Clinical Statistics Group), Matt Wessel, Greg Bakken and Jing Lu (Pfizer, Groton, Scientific Computing Group) for assistance with statistical methodology.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Mente*, S., Lombardo, F. A recursive-partitioning model for blood–brain barrier permeation. J Comput Aided Mol Des 19, 465–481 (2005). https://doi.org/10.1007/s10822-005-9001-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-005-9001-7